Polak v. Sterilite Corporation

CourtDistrict Court, N.D. Texas
DecidedMay 4, 2021
Docket3:19-cv-02972
StatusUnknown

This text of Polak v. Sterilite Corporation (Polak v. Sterilite Corporation) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Polak v. Sterilite Corporation, (N.D. Tex. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION ANTHONY POLAK, § § Plaintiff, § § Civil Action No. 3:19-CV-2972-D VS. § § STERILITE CORPORATION, § § Defendant. § MEMORANDUM OPINION AND ORDER This suit brought under the Americans with Disabilities Act of 1990 (“ADA”), 42 U.S.C. § 12101 et seq., arises from a positive random drug test that resulted in the plaintiff’s termination and from the defendant’s failure to rehire the plaintiff. The court must decide whether the plaintiff has raised a genuine issue of material fact that precludes summary judgment on his discrimination and retaliation claims. Concluding that he has not, the court grants defendant’s motion for summary judgment and dismisses this action with prejudice by judgment filed today. I Defendant Sterilite Corporation (“Sterilite”) is a company that produces various plastic products using injection molding.1 From September 2002 until April 2019, plaintiff 1In deciding Sterilite’s motion for summary judgment, the court views the evidence in the light most favorable to Polak as the summary judgment nonmovant and draws all reasonable inferences in his favor. See, e.g., Owens v. Mercedes-Benz USA, LLC, 541 F.Supp.2d 869, 870 n.1 (N.D. Tex. 2008) (Fitzwater, C.J.) (citing U.S. Bank Nat’l Ass’n v. Safeguard Ins. Co., 422 F.Supp.2d 698, 701 n.2 (N.D. Tex. 2006) (Fitzwater, J.)). Anthony Polak (“Polak”) worked at Sterilite’s Ennis, Texas plant. At the time of his termination, Polak was employed as an assistant supervisor. Sterilite maintains a Substance Abuse Policy (“Policy”) that applies to all employees.

The Policy, inter alia, prohibits “[a]ny use of drugs which are illegal under federal or state law, whether on or off Sterilite time, if the use results in drugs being present in an employee’s system while at work.” D. App. 55. It provides for post-accident drug and alcohol testing, for testing “if there is a reasonable suspicion of employee impairment while

on Sterilite’s premises or during the hours of employment based on specific facts and rational[] inferences,”2 and for “[r]andom testing, as allowed by state or local statute, at periodic intervals to maintain safety and productivity.” Id. at 56. Under the heading “Testing Procedures,” the Policy states that “Sterilite will use a variety of testing methods . . . [which] may include urinalysis, saliva, hair follicle and breath

or blood alcohol,” id.; that “urinalysis or saliva testing are the preferred methods of testing,” 2Under the Policy,

specific facts and rational[] inferences . . . may include, but are not limited to observations concerning the appearance, behavior, speech, or body odors of the employee. For example, reasonable suspicion determinations may be indicated by, among other things, the smell of alcohol, decreased cognitive function, slurred speech, bloodshot eyes, pinpoint or dilated pupils, impairment of coordination, changes in personality, erratic behavior, disorganized speech patterns, and if the employee statement does not rationally explain what was observed. D. App. 56. - 2 - id.; and that “Sterilite will use urinalysis to test for drug abuse,” id. at 57. In cases where saliva testing is used, the Policy provides: Sterilite at any time may utilize rapid oral testing swabs. The Occupational Health Nurse will administer the test and collect the specimen following the guidelines in appendix A and submit presumptive the positive specimen samples and chain of custody forms to third party laboratory. A third party service may also be utilized for saliva rapid testing. Id. Under the Policy, an employee who tests positive for illegal drugs “will be subject to disciplinary action, up to and including termination.” Id. Nevertheless, [e]mployees are entitled, upon written request to Sterilite, to obtain a copy of their test results. Employees are also entitled, upon request, to explain in a confidential setting their positive test results with a designated Sterilite representative. An employee may request to have a confirmed positive saliva or urine sample retested by another certified lab at their own expense. Id. at 58. On March 26, 2019 Polak and five other employees were randomly selected for drug testing. Sterilite used the saliva-testing method. With a swab, Polak swabbed his own cheek and under on his tongue, placed the swab in a vial and sealed it, and placed the vial in an envelope that he also sealed. Polak returned to his work following the drug test and continued to work until April 1, 2019. Sterilite submitted Polak’s saliva to Quest Diagnostics (“Quest”), a third-party lab, to perform an enzyme immunoassay (also referred to as a “rapid test”). Sterilite maintains - 3 - that, when the sample tested positive for THC3 using the rapid test, Quest tested the sample again using gas chromatography and mass spectrometry to confirm the results.4 On March 31, 2019 Quest allegedly contacted one of Sterilite’s Human Resources

Managers, Ada Jack (“Jack”), and requested that Jack have Polak contact Quest’s Medical Review Officer (“MRO”). Polak contacted the MRO, who informed Polak that his saliva sample had tested positive for THC. The following day, Jack received Polak’s positive drug test results and discussed them

with him over the telephone. Polak told Jack that he had not used marijuana in over 30 years. Polak requested to speak with a Sterilite representative about the positive test result, but no one whom he contacted responded. Polak maintains that he was never given a copy of his positive test result. Sterilite terminated Polak’s employment on April 1, 2019, allegedly because Jack believed that Polak had violated the Policy.5

3Tetrahydrocannabinol. 4Polak contends that he was notified of only one test, not a confirmatory second test, and that, when he sought employment benefits, Sterilite did not offer evidence of a confirmatory second test. Polak also objects under Fed. R. Evid. 801 and 403 and moves to strike Sterilite’s evidence that it obtained a confirmatory test of Polak’s saliva sample. Because the court does not rely on evidence of a confirmatory second test in granting Sterilite’s motion for summary judgment, it denies Polak’s motion to strike this evidence as moot. 5Polak objects to Sterilite’s evidence that Polak violated the Policy and that his employment was terminated on that ground. He maintains that this is improper lay opinion testimony that violates Fed. R. Evid. 701. The court disagrees and overrules this objection. Rule 701 provides: [i]f a witness is not testifying as an expert, testimony in the form - 4 - On April 5, 2019 Polak took a hair follicle drug test at LabCorp, a different third-party lab. He sent the test results to Jack and to Sterilite’s occupational health nurse, the Vice President of Human Resources, the Ennis facility plant manager, and the Sterilite corporate

Human Resources Manager. Sterilite maintains that Polak’s April 5, 2019 test did not comply with the Policy and that Sterilite did not reinstate Polak upon receipt of the hair follicle test because Polak did not follow the proper procedures for obtaining a retest of a confirmed positive sample.

of an opinion is limited to one that is: (a) rationally based on the witness’s perception; (b) helpful to clearly understanding the witness’s testimony or to determining a fact in issue; and (c) not based on scientific, technical, or other specialized knowledge within the scope of Rule 702.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Little v. Liquid Air Corp.
37 F.3d 1069 (Fifth Circuit, 1994)
Daigle v. Liberty Life Insurance
70 F.3d 394 (Fifth Circuit, 1995)
Seaman v. C S P H Inc
179 F.3d 297 (Fifth Circuit, 1999)
Rachid v. Jack In The Box Inc
376 F.3d 305 (Fifth Circuit, 2004)
Pinkerton v. Spellings
529 F.3d 513 (Fifth Circuit, 2008)
Crouch v. JC Penney Corp Inc
337 F. App'x 399 (Fifth Circuit, 2009)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
St. Mary's Honor Center v. Hicks
509 U.S. 502 (Supreme Court, 1993)
Gross v. FBL Financial Services, Inc.
557 U.S. 167 (Supreme Court, 2009)
Nielsen v. Moroni Feed Company
162 F.3d 604 (Tenth Circuit, 1998)
Hernandez v. Yellow Transp., Inc.
670 F.3d 644 (Fifth Circuit, 2012)
Fayette Long Jeanell Reavis v. Eastfield College
88 F.3d 300 (Fifth Circuit, 1996)
Kenneth D. Sandstad v. Cb Richard Ellis, Inc.
309 F.3d 893 (Fifth Circuit, 2002)
Thomas E. West v. Nabors Drilling Usa, Inc.
330 F.3d 379 (Fifth Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Polak v. Sterilite Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/polak-v-sterilite-corporation-txnd-2021.